Please login to the form below

Not currently logged in
Email:
Password:

The Editors blog

An inside look at what’s happening within the pharma industry and across the PMGroup from the PMLiVE editorial team

Burden of proof

Breakthroughs in Alzheimer's are sorely needed, but there's still lots of work to do on AD04
Alzheimers brain scan

Responsible for more than 60 per cent of dementia cases in Europe, Alzheimer's disease is an area desperately in need of treatment advances.

So AFFiRiS' recently announced 'breakthrough' should be a cause for celebration. But the Vienna-based biotech faces some hasty repositioning after AD02, its lead peptide-based vaccine, was beaten in a phase II trial by its AD04 comparator.

The results indicate AD04 is “the first drug ever to demonstrate clinical and biomarker effects consistent with disease modification”, according to the company, which says its effects were achieved for “at least 18 months in 47 per cent of patients”.

Breakthrough or not, AD04 still faces an uphill struggle. Drugs designed to dissolve or block the formation of amyloid plaques have consistently failed in late-stage clinical trials, often after encouraging results on cognitive measures in phase II.

And although AFFiRiS says AD04's results are the first ever to meet EMA and FDA criteria for disease modifications in Alzheimer's, the trial was not a controlled study and had no placebo group.

So a wait-and-see approach remains prudent - only further, rigorous testing will tell if AD04 really is a breakthrough.

Article by
Dominic Tyer

editorial director of PMGroup

6th June 2014

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Hanover Communications

Healthcare is evolving rapidly. To stand out from the crowd requires a potent combination of rich insight, innovative ideas and...

Latest intelligence

DEMAND DIVERSITY REPORT 02: Why is the LGBTQ+ community facing poorer health outcomes due to COVID-19?
We’re all aware that clinical trials have been discussed more widely since the COVID-19 pandemic. While that’s a great thing for raising awareness of clinical trials in general, it’s also...
CHECKLIST 04: Let’s make your patient recruitment strategies a success
From how to generate insights to define your audience to drilling down those all-important key messages, our checklist has everything you need to think of, covered....
Multichannel engagement and the need for greater understanding of European markets
By Laurence Olding and Georgina James...

Infographics